Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Herrling hints Glivec verdict may impact innovator India investments

This article was originally published in Scrip

Executive Summary

Days ahead of a Supreme Court verdict on the crucial and much publicized Glivec (imatinib mesylate) case in India, Novartis seems to be expecting an unfavourable outcome given the backdrop of a series of patent related set-backs for innovator firms. And there has been a broad hint that the outcome of the case could steer Novartis and other firms away from using India as a research base.



Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts